LEXX

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT We update investors on Lexaria Bioscience Corporation’s (NASDAQ:LEXX) latest news on the occasion of the company’s report of fiscal year 2026 first quarter financial results for the period ending November 30th, 2025. During the first quarter, the company executed a capital raise, achieved several milestones for its GLP-1 agonist studies, and extended its Material Transfer Agreement with an undisclosed pharmaceutical company. Following the quarter end, Lexaria presented its Phase Ib results for study GLP-1-H24-4, emphasizing the material reduction in side effects for DehydraTECH (DHT)-formulated semaglutide. Since our previous report in late December, Lexaria has released an annual letter from the CEO, been awarded additional patents, and reported final results from human pilot study #5 (GLP-1-H25-5). CEO Richard Christopher summarized the key achievements and objectives for Lexaria in his letter, centering on the performance of the DHT-formulated GLP-1 agonists that have been evaluated in many preclinical and clinical studies over the last several years. The most important takeaways from this work have been the reduction in adverse events compared with the injected version of the diabetes and weight loss drugs, as well as confirming the products’ ability to improve glucose, insulin, and weight using the DHT formulation. Supporting these efforts is a portfolio of 60 DHT patents granted around the world, with the most recent wave emphasizing the delivery platform’s treatment of nicotine, hypertension, epilepsy, and diabetes. Fiscal Year 2026 First Quarter Results Lexaria reported fiscal year 2026 first quarter results for the three-month period ending November 30th, 2025, through the filing of its Form 10-Q. The company reported no revenues and total operating expense of $1.6 million, resulting in net loss of ($1.6) million or ($0.07) per diluted common share. For the quarter and versus the comparable prior year period: Revenue totaled $0 compared to $184,000 as the Premier arrangement expired at the end of the last fiscal year, and no B2B product revenues were recognized compared with revenues of $174,000 and $9,923; Research and development expenses totaled $671,000, down 66% from $2.0 million, reflecting the completion of GLP-1 agonist trials, including the Phase Ib GLP-1-H24-4 study;...

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Human Pilot Study #5," stated Richard Christopher, CEO of Lexaria. "In addition to achieving the Study's primary safety and tolerability endpoint, we also demonstrated that oral DehydraTECH-liraglutide functioned comparably to traditionally injected liraglutide, consistent with our regulatory development pathway objectives," continued Mr. Christopher. "We now have compiled compelling evidence to further support examining the pursuit of the world's first oral liraglutide product." The primary results from this Study were issued on June 11, 2025, at which time Lexaria reported a 22.7% reduction in adverse events ("AEs") with DHT-LIR as compared to the SAX-LIR, with a particular emphasis on a 67% reduction in nausea and a 31% reduction in overall gastrointestinal AEs. The differences in measurements of blood glucose, insulin and body weight across most time points were not statistically significantly different, with remarkable similarity in many areas and slight differences in others. Weight loss was experienced by 9 out of 10 people in each Study arm and slightly higher in the Saxenda® Study arm; though weight loss was not a primary goal of this Study with the very short treatment period of only 1 week with each treatment. Evaluating the safety and tolerability of the oral DHT-LIR capsules relative to injected SAX-LIR was the primary endpoint of this Study. This objective was successfully met with clear signs of improved safety and tolerability performance by the DHT-LIR. Since mid-2025, Lexaria and its third-party bioanalytical service providers have invested considerable time and expertise in attempting to determine the precise pharmacokinetic ("PK") blood liraglutide quantitation and profiling results from the Study. This included the use of two different manufactured brands of commercially available ELISA (enzyme-linked immunosorbent assay) test kits. Throug...

Lexaria Bioscience (LEXX) provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH study arms relative to the Rybelsus control study arm. At week 16, rough parity was reached between the DHT arms and the Rybelsus control as there were no statistically significant treatment differences observed in terms of the numerical least squares means changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein cholesterol specifically. While both DHT-semaglutide and Rybelsus reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT-semaglutide arm showed a modest numerical LSM reduction in fat mass of -1.08 kg and in total mass of -1.40 kg, accompanied by minimal reduction in lean mass of -0.41 kg. In contrast, the Rybelsus control arm achieved greater LSM reductions in fat mass of -3.55 kg and in total mass of -5.36 kg, but also had a notably higher reduction in lean mass of -1.72 kg. This finding is considered intriguing as it possibly points to proportionally lower lean mass to fat mass bodyweight reduction potential being achievable with DHT-semaglutide. While blood pressure analysis was not formally an efficacy endpoint of the Study, it was noteworthy that the DHT-cannabidiol arm achieved meaningful reductions in blood pressure. This is of special interest since the Study participants were not generally hypertensive. At week 4, a mean change of -4.6 mmHg in systolic blood pressure and -4.0 mmHg in diastolic blood pressure was evidenced in the DHT-CBD arm. Blood pressure reductions were also evident in this arm following completion of treatment at the week 16 follow up point with a mean change of -2.6 mmHg in systolic blood pressure and -3.0 mmHg in diastolic blood pressure reported. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Ins...

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm. "We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing dataset which showcases the many potential benefits of our platform technology - DehydraTECH." "At our stage of development, clinical data is of paramount importance to us," continued Mr. Christopher. "Lexaria's "follow the science" approach and the positive results from this Study are already guiding our 2026 R&D plans as well as our business development initiatives. We are expecting exciting developments in 2026 and beyond." Secondary Efficacy Parameters At week 16, rough parity was reached between the DHT arms and the Rybelsus® control as there were no statistically significant treatment differences observed in terms of the numerical least squares means ("LSM") changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein ("LDL") cholesterol specifically (nominal p-values were >0.05). Body Composition While both DHT-semaglutide and Rybelsus® reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT‑semaglutide arm showed a modest numerical LSM reduction in fat mass of −1.08 kg and in total mass of −1.40 kg, accompanied by minimal reduction in lean mass of −0.41 kg. In contrast, the Rybelsus® control arm achieved greater LSM reductions in fat mass of −3.55 kg and in total mass of −5.36 kg, but also had a notably higher reduction in lean mass of −1.72 kg. This finding is considered intriguing as it possibly points to proportionally lower lean mass to fat mass bodyweight reduction potential being achievable with DHT-semaglutide (37.96% as compared to 48.45% for Rybelsus®). Blood Pressure Analyses W...

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this week. Activity in the obesity and GLP-1 agonist space has been robust in 2025 with a number of deals and new trial data announced. In this report we will bring investors up to date on recent activity and update near term milestones. Lexaria View on GLP-1 Agonists In the fall of 2023, Lexaria began its efforts to evaluate members of the GLP-1 agonist class formulated with DehydraTECH to determine if the new formulation could improve bioavailability, cost-effectiveness, tolerability, weight-loss potential, management of diabetes and other health conditions. Since then, the company has launched five human studies along with other non-human work to answer this question. Over the last two years, Lexaria has reported the data from these trials showing reduced levels of side effects, comparable levels of glucose reduction and insulin increase, less semaglutide necessary than in Rybelsus to achieve similar effects. In an August 6th press release, management penned a missive reviewing GLP-1 agonist market activity highlighting the primary players (Eli Lilly and Novo Nordisk), the number of drugs in development (39) and number of sponsors advancing them (34). The note from management also addressed the dealmaking environment around the class, underlining the collaboration between Novo Nordisk and Septerna, Roche’s asset acquisition from Zealand Pharma, Regeneron’s licensing deal with Hansoh Pharmaceuticals and Merck and Cyprumed, which we discussed in our previous report. In late August, Eli Lilly announced data from its Phase III trial evaluating its oral GLP-1 receptor agonist, orforglipron. The study met all of its primary and secondary endpoints. With the completion of the study, Lilly has all the clinical data necessary to submit orforglipron for approval globally. Availability of an oral for Eli Lilly could raise the stakes for having an oral version of this class of drug and benefit Lexaria as others find other oral solutions for GLP-1 agonist delivery. Lexaria’s data co...

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third quarter 2025 results via the filing of its Form 10-Q. Since our previous quarterly report at the end of April, the company has provided an update on its Material Transfer Agreement, attended BIO, completed the GLP-1-H25-5 study and reached a milestone of 50 patents granted worldwide. The company also compiled key safety data from its GLP-1-H24-4 study supporting the favorable safety and tolerability profile of DehydraTECH (DHT) -formulated GLP-1 agonists. In this report we will bring investors up to date on recent activity and review third quarter financial performance. Third Quarter 2025 Results Lexaria filed its Form 10-Q reporting quarterly results for the three-month period ending May 31st, 2025. The company reported revenues of $174,000 and total operating expense of $3.8 million resulting in net loss of ($3.8) million or ($0.21) per diluted common share. For its fiscal third quarter and versus the comparable prior year period: Revenue totaled $174,000, up 107% from $84,000 due to increases in licensing revenues related to the agreement with Premier; Research and development expenses totaled $2.7 million, up 370% from $0.6 million as a result of increased expenses related to the Phase Ib GLP-1 agonist trial and investigational drug product manufacturing; General and administrative expenses totaled $1.2 million down 4% from $1.3 million due to lower accounting and professional fees; Interest income was essentially $0 in both periods; Other loss of ($40,000) represented unrealized loss on marketable securities related to decreases in fair value; Net loss was ($3.8) million, or ($0.21) per share, compared to net loss of ($1.8) million or ($0.13) per share. As of May 31st, 2025, cash and marketable securities totaled $4.6 million which compares to $6.6 million at the end of fiscal year 2024. Cash burn for the first nine months of FY:25 was approximately ($7.9) million. Cash from financing over the same period totaled $6.0 million from equity sales. Management estimates that the company holds sufficient cash to meet its financial obligations until second quarter 2026. Cyprumed Partnership Deal activity has picked up in recent months with almost 90 transactions taking place year to date. We see this as a good sign as esta...

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and 5 relative to the Rybelsus® control study arm 4. "We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate obvious superiority in reducing unwanted side effects compared to the world's only approved oral-based GLP-1 medication, Rybelsus®." Adverse Events After 8 weeks of treatment, Lexaria's DehydraTECH-GLP-1 arms are tracking very nicely from a safety and tolerability perspective relative to the Rybelsus® control arm; most notably in terms of reductions in the incidence of gastrointestinal ("GI") adverse events ("AEs"): n = number of patients included in each study group for safety and tolerability assessments Of note, every person taking Rybelsus® in the Study experienced at least one AE. There was a 20.8% reduction in the overall number of persons experiencing an AE with DehydraTECH-semaglutide ("DHT-semaglutide") vs. Rybelsus® and a 36.5% reduction in the total quantity of AEs derived from DHT-semaglutide vs. Rybelsus®. There was also a 43.5% reduction in GI AEs from persons taking DHT-semaglutide vs. Rybelsus®. In Novo Nordisk's® Semaglutide Treatment Effect in People with obesity (STEP) studies, across a patient population of 3,331 people, 2,934 or 88.1% of them experienced AEs of any kind. Through 8 weeks, only 79.2% of patients in the DHT-semaglutide study arm have experienced AEs of any kind, meaning 10.1% fewer patients in the DHT-semaglutide study arm experienced AEs relatively speaking. Potentially removing all AEs from 10% of a patient population that is currentl...

Revenue: US$174.0k (up 107% from 3Q 2024). Net loss: US$3.79m (loss widened by 113% from 3Q 2024). US$0.21 loss per share (further deteriorated from US$0.13 loss in 3Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 27%. Earnings per share (EPS) missed analyst estimates by 45%. Looking ahead, revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 7.4% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Lexaria Bioscience (at least 2 which shouldn't be ignored), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.